加载中...

MedXY AI/MedXY News/Tag: obesity

MedXY News

EnglishTag

obesity

98 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Simultaneous Liver Transplant and Sleeve Gastrectomy: A Dual Approach to Combat Obesity and MASLD with Durable Outcomes

Simultaneous Liver Transplant and Sleeve Gastrectomy: A Dual Approach to Combat Obesity and MASLD with Durable Outcomes

Combining liver transplant with sleeve gastrectomy yields sustained weight loss, improved metabolic syndrome, and reduced liver allograft steatosis, without increasing mortality or graft loss, offering an effective treatment for obese patie

Section: GastroenterologyOct 27, 2025

Bariatric Surgery Significantly Reduces Risk of Developing Major Obesity-Related Comorbidities: Insights from a Large Veterans Cohort

Bariatric Surgery Significantly Reduces Risk of Developing Major Obesity-Related Comorbidities: Insights from a Large Veterans Cohort

A large retrospective cohort study reveals bariatric surgery markedly lowers the incidence of key metabolic comorbidities compared to weight management alone in obese veterans, supporting its role in durable obesity-related risk reduction.

Section: Diabetes & EndocrinologyOct 27, 2025

Comparative Effectiveness and Costs of Bariatric Surgery Versus GLP-1 Receptor Agonists in Obesity Management

Comparative Effectiveness and Costs of Bariatric Surgery Versus GLP-1 Receptor Agonists in Obesity Management

This article reviews recent evidence comparing weight loss outcomes and healthcare costs of bariatric surgery and GLP-1 receptor agonists, highlighting implications for clinical decision-making in treating class II and III obesity.

Section: Internal MedicineOct 27, 2025

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudat

Section: Diabetes & EndocrinologyOct 26, 2025

Integrating Obesity Management into Cardiac Rehabilitation: Challenges, Evidence, and Future Directions

Integrating Obesity Management into Cardiac Rehabilitation: Challenges, Evidence, and Future Directions

Obesity management in cardiac rehabilitation (CR) is underutilized despite its cardiovascular benefits. This review explores the evidence, complexities, patient perspectives, and healthcare provider attitudes, emphasizing tailored strategie

Section: CardiologyOct 24, 2025

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychi

Section: Diabetes & EndocrinologyOct 22, 2025

Revisiting Obesity Classification: Insights from a Population-Based Survey in Peru Using New Clinical Frameworks

Revisiting Obesity Classification: Insights from a Population-Based Survey in Peru Using New Clinical Frameworks

This review examines a landmark Peruvian study applying new obesity definitions that incorporate clinical dysfunction and adiposity measures beyond BMI, revealing substantial underdiagnosis with traditional approaches and ethnic variation i

Section: Diabetes & EndocrinologyOct 20, 2025

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.

Section: Diabetes & EndocrinologyOct 19, 2025

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.

Section: Diabetes & EndocrinologyOct 19, 2025

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health

This systematic review and meta-analysis evaluates the effects of obesity interventions—lifestyle modification, pharmacotherapy, and bariatric surgery—on male fertility, highlighting improvements with lifestyle changes and limited benefits

Section: Diabetes & EndocrinologyOct 13, 2025

Preserving Bone Quality in Older Adults with Obesity Through Lifestyle Intervention: Insights from the LIMB-Q Trial

Preserving Bone Quality in Older Adults with Obesity Through Lifestyle Intervention: Insights from the LIMB-Q Trial

The LIMB-Q trial demonstrates that intensive lifestyle interventions combining weight management and exercise preserve bone quality in older adults with obesity, despite significant weight loss, highlighting a promising approach for mitigat

Section: Diabetes & EndocrinologyOct 7, 2025

From Plate to Progress: Five Scientifically Proven Diets to Help Manage Obesity Effectively

From Plate to Progress: Five Scientifically Proven Diets to Help Manage Obesity Effectively

Explore five scientifically supported dietary patterns that aid effective weight loss for individuals struggling with obesity, emphasizing balanced nutrition and sustainable lifestyle changes.

Section: Family Medicine & NutritionOct 8, 2025

Time-Restricted Eating in Overweight Adults: Effects on Sleep, Mood, and Quality of Life Remain Neutral

Time-Restricted Eating in Overweight Adults: Effects on Sleep, Mood, and Quality of Life Remain Neutral

A randomized clinical trial found that different timing schedules of an 8-hour time-restricted eating window combined with Mediterranean diet education did not significantly affect sleep, mood, or quality of life in adults with overweight o

Section: Clinical UpdatesOct 8, 2025

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.

Section: CardiologyOct 8, 2025

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.

Section: Clinical UpdatesOct 8, 2025

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.

Section: Diabetes & EndocrinologyOct 8, 2025

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

A 12-week prospective study demonstrates tirzepatide significantly improves insulin sensitivity in obese Japanese patients with type 2 diabetes, independent of weight loss, as assessed by hyperinsulinaemic-euglycaemic clamp.

Section: Clinical UpdatesOct 8, 2025

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss

Combining aerobic and resistance exercise with diet-induced weight loss in obese older adults significantly improves insulin secretion, preserves CNTFRα levels, and increases IGF-1, enhancing metabolic and physical function.

Section: Clinical UpdatesOct 8, 2025

Synergistic Effects of Combined Aerobic and Resistance Exercise with Diet on Insulin Secretion and Neurotrophic Factors in Older Adults with Obesity

Synergistic Effects of Combined Aerobic and Resistance Exercise with Diet on Insulin Secretion and Neurotrophic Factors in Older Adults with Obesity

Combining aerobic and resistance exercise with diet-induced weight loss in older adults with obesity significantly improves insulin secretion, metabolic health, and physical function, likely mediated by ciliary neurotrophic factor receptor

Section: Clinical UpdatesOct 8, 2025

Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity

Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity

Intraduodenal calcium at doses up to 1000 mg amplifies the anorexigenic effects of L-tryptophan by boosting gut hormones CCK, GLP-1, and PYY, reducing energy intake in obese males, highlighting a novel adjunctive approach for appetite regul

Section: Clinical UpdatesOct 8, 2025

Prev 1 2 3 4 5 Next